Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene LabBGLC +4.67%58 Altman Z-Score is 1.61 as of Jul. 16, 2026, which is 88% below its 10-year median of 13.66. GuruFocus rates BGLC with a GF Score™ of 58/100 and a GF Value™ of $2.17 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,562 Chemicals companies, BioNexus Gene Lab ranks worse than 82.71% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 1.61 is in distress zone. This implies bankruptcy possibility in the next two years.
BioNexus Gene Lab has a Altman Z-Score of 1.61, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for BioNexus Gene Lab's Altman Z-Score or its related term are showing as below:
BGLC'
s Altman Z-Score Range Over the Past 10 Years
Min: 1.6 Med: 13.66 Max: 1138.66
Current: 1.61
During the past 8 years, BioNexus Gene Lab's highest Altman Z-Score was 1138.66. The lowest was 1.60. And the median was 13.66.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
BioNexus Gene Lab Altman Z-Score Related Terms
BioNexus Gene Lab Altman Z-Score Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLC vs QGAI, VYST, GLGI: Altman Z-Score Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab Altman Z-Score vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
BioNexus Gene Lab's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.4867
+
1.4
*
-0.7711
+
3.3
*
-0.3195
+
0.6
*
4.2883
+
1.0
*
0.5875
=
1.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
BioNexus Gene Lab (BGLC) has a Altman Z-Score of 1.61 as of Jul. 16, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on BioNexus Gene Lab and its competitors. This is 88% below median its historical median of 13.66. Over the past decade, BioNexus Gene Lab's Altman Z-Score has ranged from 1.60 to 1,138.66. According to the industry distribution chart, BioNexus Gene Lab ranks #1292 out of 1562 companies in the Chemicals industry, placing it in the top 82.7%.
Is BioNexus Gene Lab's Altman Z-Score too high?
BioNexus Gene Lab's current Altman Z-Score of 1.61 is 88% below median its 10-year median of 13.66. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 1,138.66. The Chemicals industry median Altman Z-Score is 3.13. BioNexus Gene Lab's value of 1.61 is 48.6% below this industry median. Based on the distribution chart, BioNexus Gene Lab ranks #1292 out of 1562 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Altman Z-Score compare to QGAI and VYST?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #1292 out of 1562 companies for Altman Z-Score. This places BioNexus Gene Lab in the lower half of its industry. The industry median Altman Z-Score is 3.13. BioNexus Gene Lab's value of 1.61 is 48.6% below this benchmark. Historically, BioNexus Gene Lab's own Altman Z-Score has ranged from 1.60 to 1,138.66 over the past decade. While the company's 10-year median is 13.66 vs. the industry median of 3.13, BioNexus Gene Lab has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Chemicals company?
The median Altman Z-Score among Chemicals companies is 3.13, based on 1,562 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioNexus Gene Lab's current Altman Z-Score of 1.61 is 48.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on BioNexus Gene Lab and its competitors. For the Chemicals industry, the median Altman Z-Score is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current Altman Z-Score is 1.61, which is 88% below median its own 10-year median of 13.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $1.68 — trading 22.6% below its estimated fair value. The current Altman Z-Score is 1.61, which is 88% below median its 10-year median of 13.66 and 48.6% below the Chemicals industry median of 3.13. BioNexus Gene Lab's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Altman Z-Score is 1.61 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.68 is trading 22.6% below its estimated GF Value™ of $2.17.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
Altman Z-Score: 1.61 (88% below median its 10-year median of 13.66)
GF Value™: $2.17 vs. price of $1.68 (22.6% below fair value)
Industry Position: 48.6% below the Chemicals median (#1292 of 1562)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
58GF Score
Get the complete analysis for BGLC
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
